Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells

Biochemical Journal

Volumn 454, Issue 2, 2013, Pages 283-293

  Wiejak, Jolanta ^a   Dunlop, Julia ^a   Mackay, Simon P ^b   Yarwood, Stephen J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Flavanoid; Gene expression; Interleukin 6 (IL 6); Janus kinase signal transducer and activator of transcription (JAK STAT); Suppressor of cytokine signalling 3 (SOCS3)

Indexed keywords

1,1' (1,2 ETHENEDIYL)DIBENZENE; 4H CHROMEN 4 ONE; 5 [2 (4 HYDROXYPHENYL)VINYL] 1,3 BENZENEDIOL; FLAVANOID; FLAVONE; INTERLEUKIN 6; ISOFLAVONE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NARINGENIN; RESVERATROL; STAT3 PROTEIN; STILBENE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; ENDOTHELIUM CELL; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VASCULAR ENDOTHELIUM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CYTOKINE RECEPTOR GP130; ENDOTHELIUM, VASCULAR; FLAVONOIDS; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT; MICE; MUTANT PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84881531764     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20130481     Document Type: Article

References (47)

1. Bruunsgaard, H., Pedersen, M. and Pedersen, B. K. (2001) Aging and proinflammatory cytokines. Curr. Opin. Hematol. 8, 131-136
2. Calabro, P., Limongelli, G., Pacileo, G., Di Salvo, G., Golino, P. and Calabro, R. (2008) The role of adiposity as a determinant of an inflammatory milieu. J. Cardiovasc. Med. 9, 450-460
3. Schuett, H., Oestreich, R., Waetzig, G. H., Annema, W., Luchtefeld, M., Hillmer, A., Bavendiek, U., von Felden, J., Divchev, D., Kempf, T. et al. (2012) Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arteriosclerosis 32, 281-290
4. Lee, J. M., Kim, S. R., Yoo, S. J., Hong, O. K., Son, H. S. and Chang, S. A. (2009) The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J. Int. Med. Res. 37, 1803-1812
5. Schieffer, B., Selle, T., Hilfiker, A., Hilfiker-Kleiner, D., Grote, K., Tietge, U. J., Trautwein, C., Luchtefeld, M., Schmittkamp, C., Heeneman, S. et al. (2004) Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110, 3493-3500
6. von der Thusen, J. H., Kuiper, J., van Berkel, T. J. and Biessen, E. A. (2003) Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. 55, 133-166
7. Brod, S. A. (2000) Unregulated inflammation shortens human functional longevity. Inflammation Res. 49, 561-570
8. Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Muller-Newen, G. and Schaper, F. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20
9. Hou, T., Tieu, B. C., Ray, S., Recinos, III, A., Cui, R., Tilton, R. G. and Brasier, A. R. (2008) Roles of IL6-gp130 signaling in vascular inflammation. Curr. Cardiol. Rev. 4, 179-192
10. Sands, W. A., Woolson, H. D., Milne, G. R., Rutherford, C. and Palmer, T. M. (2006) Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells. Mol. Cell. Biol. 26, 6333-6346
11. Yoshimura, A., Naka, T. and Kubo, M. (2007) SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7, 454-465
12. Tan, J. C. and Rabkin, R. (2005) Suppressors of cytokine signaling in health and disease. Pediatr. Nephrol. 20, 567-575
13. Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J. A. and Yoshimura, A. (1999) Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4, 339-351
14. White, G. E., Cotterill, A., Addley, M. R., Soilleux, E. J. and Greaves, D. R. (2011) Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation. J. Mol. Histol. 42, 137-151
15. Croker, B. A., Kiu, H., Pellegrini, M., Toe, J., Preston, S., Metcalf, D., O'Donnell, J. A., Cengia, L. H., McArthur, K., Nicola, N. A. et al. (2012) IL6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunol. Cell Biol. 90, 124-129
16. Croker, B. A., Kiu, H. and Nicholson, S. E. (2008) SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol. 19, 414-422
17. Jo, D., Liu, D., Yao, S., Collins, R. D. and Hawiger, J. (2005) Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat. Med. 11, 892-898
18. Auernhammer, C. J., Bousquet, C. and Melmed, S. (1999) Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc. Natl. Acad. Sci. U.S.A. 96, 6964-6969
19. Ehlting, C., Haussinger, D. and Bode, J. G. (2005) Sp3 is involved in the regulation of SOCS3 gene expression. Biochem. J. 387, 737-745
20. Matthews, J., Almlof, T., Kietz, S., Leers, J. and Gustafsson, J. A. (2005) Estrogen receptor-α regulates SOCS-3 expression in human breast cancer cells. Biochem. Biophys. Res. Commun. 335, 168-174
21. Wiejak, J., Dunlop, J., Stoyle, C., Lappin, G., McIlroy, A., Pediani, J. D., Gao, S. and Yarwood, S. J. (2012) The protein kinase C inhibitor, Ro-31-7459, is a potent activator of ERK and JNK MAP kinases in HUVECs and yet inhibits cyclic AMP-stimulated SOCS-3 gene induction through inactivation of the transcription factor c-Jun. Cell. Signalling 24, 1690-1699
22. Mulvihill, E. E. and Huff, M. W. (2010) Antiatherogenic properties of flavonoids: implications for cardiovascular health. Can. J. Cardiol. 26, 17A-21A
23. Chanet, A., Milenkovic, D., Deval, C., Potier, M., Constans, J., Mazur, A., Bennetau-Pelissero, C., Morand, C. and Berard, A. M. (2011) Naringin, the major grapefruit flavonoid, specifically affects atherosclerosis development in diet-induced hypercholesterolemia in mice. J. Nutr. Biochem. 23, 469-477
24. Wiejak, J., Dunlop, J., Gao, S., Borland, G. and Yarwood, S. J. (2012) Extracellular signal-regulated kinase mitogen-activated protein kinase-dependent SOCS-3 gene induction requires c-Jun, signal transducer and activator of transcription 3, and specificity protein 3 transcription factors. Mol. Pharmacol. 81, 657-668
25. O'Rourke, L. and Shepherd, P. R. (2002) Biphasic regulation of extracellular-signal-regulated protein kinase by leptin in macrophages: role in regulating STAT3 Ser727 phosphorylation and DNA binding. Biochem. J. 364, 875-879
26. Yang, Y. P., Chang, Y. L., Huang, P. I., Chiou, G. Y., Tseng, L. M., Chiou, S. H., Chen, M. H., Chen, M. T., Shih, Y. H., Chang, C. H. et al. (2012) Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J. Cell. Physiol. 227, 976-993
27. Zygmunt, K., Faubert, B., MacNeil, J. and Tsiani, E. (2010) Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK. Biochem. Biophys. Res. Commun. 398, 178-183
28. Bain, J., McLauchlan, H., Elliott, M. and Cohen, P. (2003) The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204
29. Yarwood, S. J., Borland, G., Sands, W. A. and Palmer, T. M. (2008) Identification of CCAAT/enhancer-binding proteins as exchange protein activated by cAMP-activated transcription factors that mediate the induction of the SOCS-3 gene. J. Biol. Chem. 283, 6843-6853
30. Borland, G., Bird, R. J., Palmer, T. M. and Yarwood, S. J. (2009) Activation of protein kinase Cα by EPAC1 is required for the ERK- and CCAAT/enhancer-binding protein β-dependent induction of the SOCS-3 gene by cyclic AMP in COS1 cells. J. Biol. Chem. 284, 17391-17403
31. Davies, S. P., Reddy, H., Caivano, M. and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
32. Woolson, H. D., Thomson, V. S., Rutherford, C., Yarwood, S. J. and Palmer, T. M. (2009) Selective inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via Epac1-dependent induction of suppressor of cytokine signalling-3. Cell. Signalling 21, 1706-1715
33. Lolli, G., Cozza, G., Mazzorana, M., Tibaldi, E., Cesaro, L., Donella-Deana, A., Meggio, F., Venerando, A., Franchin, C., Sarno, S. et al. (2012) Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry 51, 6097-6107
34. Rebholz, H., Nishi, A., Liebscher, S., Nairn, A. C., Flajolet, M. and Greengard, P. (2009) CK2 negatively regulates Gαs signaling. Proc. Natl. Acad. Sci. U.S.A. 106, 14096-14101
35. Park, S. J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A. L. et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421-433
36. Boly, R., Gras, T., Lamkami, T., Guissou, P., Serteyn, D., Kiss, R. and Dubois, J. (2011) Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int. J. Oncol. 38, 833-842
37. Williams, R. J., Spencer, J. P. and Rice-Evans, C. (2004) Flavonoids: antioxidants or signalling molecules? Free Radical Biol. Med. 36, 838-849
38. Lamoral-Theys, D., Pottier, L., Dufrasne, F., Neve, J., Dubois, J., Kornienko, A., Kiss, R. and Ingrassia, L. (2010) Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr. Med. Chem. 17, 812-825
39. Polier, G., Ding, J., Konkimalla, B. V., Eick, D., Ribeiro, N., Kohler, R., Giaisi, M., Efferth, T., Desaubry, L., Krammer, P. H. and Li-Weber, M. (2011) Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis. 2011, 66
40. Isaacs, J. D. (2009) Antibody engineering to develop new antirheumatic therapies. Arthritis Res. Ther. 11, 225
41. Perrier, C. and Rutgeerts, P. (2012) New drug therapies on the horizon for IBD. Dig. Dis. 1, 100-105
42. Quaedackers, M. E., Mol, W., Korevaar, S. S., van Gurp, E. A., van Ijcken, W. F., Chan, G., Weimar, W. and Baan, C. C. (2009) Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 88, 1002-1009
43. Williams, J. J. and Palmer, T. M. (2012) Unbiased identification of substrates for the Epac1-inducible E3 ubiquitin ligase component SOCS-3. Biochem. Soc. Trans. 40, 215-218
44. Choi, Y. J., Kang, J. S., Park, J. H., Lee, Y. J., Choi, J. S. and Kang, Y. H. (2003) Polyphenolic flavonoids differ in their antiapoptotic efficacy in hydrogen peroxide-treated human vascular endothelial cells. J. Nutr. 133, 985-991
45. Kanno, S., Tomizawa, A., Hiura, T., Osanai, Y., Shouji, A., Ujibe, M., Ohtake, T., Kimura, K. and Ishikawa, M. (2005) Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol. Pharm. Bull. 28, 527-530
46. Erlund, I., Meririnne, E., Alfthan, G. and Aro, A. (2001) Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J. Nutr. 131, 235-241
47. Zaharko, D. S., Grieshaber, C. K., Plowman, J. and Cradock, J. C. (1986) Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors. Cancer Treat. Rep. 70, 1415-1421